Cargando…

TP53 wild-type/PPM1D mutant diffuse intrinsic pontine gliomas are sensitive to a MDM2 antagonist

Diffuse intrinsic pontine gliomas (DIPGs) are high-grade tumors of the brainstem that often occur in children, with a median overall survival of less than one year. Given the fact that DIPGs are resistant to chemotherapy and are not amenable to surgical resection, it is imperative to develop new the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xu, Cheng, Liu, Heng, Pirozzi, Christopher J., Chen, Lee H., Greer, Paula K., Diplas, Bill H., Zhang, Liwei, Waitkus, Matthew S., He, Yiping, Yan, Hai
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8565061/ https://www.ncbi.nlm.nih.gov/pubmed/34732238 http://dx.doi.org/10.1186/s40478-021-01270-y

Ejemplares similares

DIPG-53. CHARACTERIZING THE ROLE OF PPM1D MUTATIONS IN THE PATHOGENESIS OF DIFFUSE INTRINSIC PONTINE GLIOMAS (DIPGS)
por: Khadka, Prasidda, et al.
Publicado: (2020)

Expression signature based on TP53 target genes doesn't predict response to TP53-MDM2 inhibitor in wild type TP53 tumors
por: Sonkin, Dmitriy
Publicado: (2015)

TP53 mutant MDM2-amplified cell lines selected for resistance to MDM2-p53 binding antagonists retain sensitivity to ionizing radiation
por: Drummond, Catherine J., et al.
Publicado: (2016)

Functionalized Macrophage Exosomes with Panobinostat and PPM1D‐siRNA for Diffuse Intrinsic Pontine Gliomas Therapy
por: Shan, Shaobo, et al.
Publicado: (2022)

MDM4 expression as an indicator of TP53 reactivation by combined targeting of MDM2 and MDM4 in cancer cells without TP53 mutation
por: Hirose, Mitsuaki, et al.
Publicado: (2014)

Mining cancer genomes for change-of-metabolic-function mutations
por: Tu, Kevin J., et al.
Publicado: (2023)

Mutant allele quantification reveals a genetic basis for TP53 mutation-driven castration resistance in prostate cancer cells
por: Lei, Kefeng, et al.
Publicado: (2018)

MDM4 Overexpressed in Acute Myeloid Leukemia Patients with Complex Karyotype and Wild-Type TP53
por: Li, Li, et al.
Publicado: (2014)

Effects of MDM2, MDM4 and TP53 Codon 72 Polymorphisms on Cancer Risk in a Cohort Study of Carriers of TP53 Germline Mutations
por: Fang, Shenying, et al.
Publicado: (2010)

MDM2 is a potential therapeutic target and prognostic factor for ovarian clear cell carcinomas with wild type TP53
por: Makii, Chinami, et al.
Publicado: (2016)

Low Prevalence of TP53 Mutations and MDM2 Amplifications in Pediatric Rhabdomyosarcoma
por: Ognjanovic, Simona, et al.
Publicado: (2012)

TP53 and MDM2 polymorphisms and the risk of endometrial cancer in postmenopausal women
por: Zając, Agnieszka, et al.
Publicado: (2014)

High Expression of PPM1D Induces Tumors Phenotypically Similar to TP53 Loss-of-Function Mutations in Mice
por: Milosevic, Jelena, et al.
Publicado: (2021)

Combined MEK/MDM2 inhibition demonstrates antitumor efficacy in TP53 wild-type thyroid and colorectal cancers with MAPK alterations
por: Pairawan, Seyed, et al.
Publicado: (2022)

MDM2 overexpression is rare in ovarian carcinoma irrespective of TP53 mutation status.
por: Foulkes, W. D., et al.
Publicado: (1995)

ATRT-08. TARGETING THE TP53-MDM2 ENHANCES RADIATION SENSITIVITY IN ATRT
por: Alimova, Irina, et al.
Publicado: (2021)

Expression of wild-type and mutated TP53 in breast carcinomas
por: Baumbusch, LO, et al.
Publicado: (2005)

TP53 and MDM2 gene polymorphisms and risk of hepatocellular carcinoma among Italian patients
por: Di Vuolo, Valeria, et al.
Publicado: (2011)

Investigation of ATM, TP53 and MDM2 polymorphisms and their association with outcome of radiotherapy for prostate cancer
por: Cintra, Hellen S, et al.
Publicado: (2013)

Polymorphisms in MDM2 and TP53 Genes and Risk of Developing Therapy-Related Myeloid Neoplasms
por: Cabezas, Maria, et al.
Publicado: (2019)

Genomic Insights into Diffuse Intrinsic Pontine Glioma
por: Lapin, Danielle H., et al.
Publicado: (2017)

Nonsense-mediated mRNA decay inhibition synergizes with MDM2 inhibition to suppress TP53 wild-type cancer cells in p53 isoform-dependent manner
por: Li, Ying, et al.
Publicado: (2022)

Enhanced G1 arrest and apoptosis via MDM4/MDM2 double knockdown and MEK inhibition in wild-type TP53 colon and gastric cancer cells with aberrant KRAS signaling
por: Wang, Xiaoxuan, et al.
Publicado: (2021)

The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis
por: Leroy, Bernard, et al.
Publicado: (2013)

Maspin subcellular expression in wild-type and mutant TP53 gastric cancers
por: Gurzu, Simona, et al.
Publicado: (2020)

Individual and combined effect of TP53, MDM2, MDM4, MTHFR, CCR5, and CASP8 gene polymorphisms in lung cancer
por: Stumbryte, Ausra, et al.
Publicado: (2017)

Design of indole- and MCR-based macrocycles as p53-MDM2 antagonists
por: Neochoritis, Constantinos G, et al.
Publicado: (2019)

CDK4 inhibition diminishes p53 activation by MDM2 antagonists
por: Sriraman, Anusha, et al.
Publicado: (2018)

Impact of TP53 Codon 72 and MDM2 SNP 309 Polymorphisms in Pancreatic Ductal Adenocarcinoma
por: Hori, Yasuki, et al.
Publicado: (2015)

Period2 downregulation inhibits glioma cell apoptosis by activating the MDM2-TP53 pathway
por: Zhanfeng, Niu, et al.
Publicado: (2016)

Molecular chaperones in the acquisition of cancer cell chemoresistance with mutated TP53 and MDM2 up-regulation
por: Tracz-Gaszewska, Zuzanna, et al.
Publicado: (2017)

Single-cell analysis reveals selection of TP53-mutated clones after MDM2 inhibition
por: Maslah, Nabih, et al.
Publicado: (2022)

Targeting the TP53/MDM2 axis enhances radiation sensitivity in atypical teratoid rhabdoid tumors
por: Alimova, Irina, et al.
Publicado: (2022)

Phase 1 Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type TP53
por: Saleh, Mansoor N., et al.
Publicado: (2021)

CRISPR screens are feasible in TP53 wild‐type cells
por: Brown, Kevin R, et al.
Publicado: (2019)

Genomic Characterization of TP53–Wild-Type Esophageal Carcinoma()
por: Quaas, Alexander, et al.
Publicado: (2018)

Chemokine Network and Overall Survival in TP53 Wild-Type and Mutant Ovarian Cancer
por: Ignacio, Rosa Mistica C., et al.
Publicado: (2018)

Nutlin-3, A p53-Mdm2 Antagonist for Nasopharyngeal Carcinoma Treatment
por: Yee-Lin, Voon, et al.
Publicado: (2018)

Correction: Phase I Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type TP53
por: Saleh, Mansoor N., et al.
Publicado: (2022)

Genetic polymorphisms of MDM2 and TP53 genes are associated with risk of nasopharyngeal carcinoma in a Chinese population
por: Xiao, Mang, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_phmn0v8ahepcul06ff73ekf5ju